Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule featuring a thieno[3,2-b]pyridine ring system with a sulfonic acid group and an amide moiety linked to a pyrrolidine ring. It is classified as an experimental drug and has not been approved for clinical use. The molecule was designed as part of research into selective enzyme inhibitors—specifically targeting coagulation factor X (F10), which plays a central role in the blood coagulation cascade. Structural studies show it binds to the active site of factor X with high affinity (Ki = 18 nM), acting as an inhibitor. There are no known approved indications or ongoing clinical trials for this compound; its primary relevance is in biochemical and structural studies related to anticoagulation and serine protease inhibition.[2][7][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thieno[3,2-b]pyridine-2-sulfonic acid [2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-pyrrolidin-3-yl]-amide.